Carboplatin and vinorelbine combined with subcutaneous interleukin-2 in metastatic melanoma with poor prognosis

Anticancer Research

Volumn 29, Issue 5, 2009, Pages 1755-1759

  Vuoristo, Meri Sisko ^a   Vihinen, Pia ^b   Skyttä, Tanja ^a   Tyynelä, Kristiina ^c   Kellokumpu Lehtinen, Pirkko ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Carboplatin; Interleukin 2; Melanoma; Metastatic; Second line treatment; Vinorelbine

Indexed keywords

CARBOPLATIN; INTERLEUKIN 2; NAVELBINE;

ADULT; ANAMNESIS; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER METASTASIS; LIVER TOXICITY; MALE; MELANOMA; METASTASIS; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; VINBLASTINE;

EID: 67650083161     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Huncharek M, Caubet JF and McGarry R: Single agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3,273 patients from 20 randomized trials. Melanoma Res 11: 75-81, 2001.
2. Nashan D, Müller ML, Grabbe S, Wustlich S and Enk A: Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine. J Eur Acad Dermatol Venereol 21: 1305-1318, 2007. (Pubitemid 350027157)
3. Atkins MB: Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res 12: 2353s-2358s, 2006.
4. Tawbi HA and Kirkwood JM: Management of metastatic melanoma. Semin Oncol 34: 532-545, 2007.
5. Whitehead RP, Moon J, McCachren SS, Hersh EM, Samlowski WE, Beck JT, Tchekmedyian NS and Sondak VK: A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study. Cancer 100: 1699-1704, 2004. (Pubitemid 38456348)
6. Jimeno A, Hitt R, Quintela-Fandino M and Cortés-Funes H: Phase II trial of vinorelbine tartrate in patients with treatment-naive metastatic melanoma. Anticancer Drags 16: 53-57, 2005.
7. Retsas S, Mohith A and Mackenzie H: Taxol and vinorelbine: a new active combination for disseminated malignant melanoma. Anticancer Drugs 7: 161-165, 1996. (Pubitemid 26150557)
8. Feun LG, Savaraj N, Hurley J, Marini A and Lai S: A clinical trial of intravenous vinorelbine tartrate plus tamoxifen in the treatment of patients with advanced malignant melanoma. Cancer 88: 584-1558, 2000. (Pubitemid 30056933)
9. Gogas H, Bafaloukos D, Aravantinos G, Fountzilas G, Tsoutsos D, Panagiotou P, Frangia K, Kalofonos HP, Briasoulis E, Castana O, Polyzos A, Pectasides D and Ioannovich J; Hellenic Cooperative Oncology Goup: Vinorelbine in combination with interleukin-2 as second-line treatment in patients with metastatic melanoma. A phase II study of the Hellenic Cooperative Oncology Group. Cancer Invest 22: 832-839, 2004.
10. Fruehauf JP, Kong KM and Jakowatz JG: Docetaxel and vinorelbine plus GM-CSF in malignant melanoma. Oncology (Williston Park) 19(4 Suppl 2): 19-22, 2005.
11. Bafaloukos D, Fountzilas G, Skarlos D, Pavlidis N, Bakoyiannis C, Karvounis N and Kosmidis P: Subcutaneous low doses of interleukin-2 and recombinant interferon alpha with carboplatin and vinblastine in patients with advanced melanoma. Oncology 55: 48-52, 1998. (Pubitemid 128707623)
12. Agarwala SS, Ferri W, Gooding W and Kirkwood JM: A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer 85: 1979-1984, 1999.
13. Jelić S, Babović N, Stamatović L, Kreacić M, Matković S and Popov I: Vinblastin-carboplatin for metastatic cutaneous melanoma as first-line chemotherapy and in dacarbazine failures: a single-center study. Med Oncol 18: 189-195, 2001. (Pubitemid 33097346)
14. Hodi FS, Soiffer RJ, Clark J, Finkelstein DM and Haluska FG: Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol 25: 283-286, 2002. (Pubitemid 34602552)
15. Zimpfer-Rechner C, Hofmann U, Figl R, Becker JC, Trefzer U, Keller I, Hauschild A and Schadendorf D: Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res 13: 531-536, 2003.
16. Rao RD, Holtan SG, Ingle JN, Croghan GA, Kottschade LA, Creagan ET, Kaur JS, Pitot HC and Markovic SN: Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer 106: 375-382, 2006. (Pubitemid 43100447)
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000. (Pubitemid 30099779)
18. Collaborative Ocular Melanoma Study Group: Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma. Arch Ophthalmol 123: 1639-1643, 2005.
19. Güven K, Kittler H, Wolff K and Pehamberger H: Cisplatin and carboplatin combination as second-line chemotherapy in dacarbazine-resistant melanoma patients. Melanoma Res 11: 411-415, 2001. (Pubitemid 32735232)
20. Hofmann MA, Gabriel V, Milling A, Kiecker F, Sterry W and Trefzer U: High-dose platinum combination therapy in pretreated patients with disseminated melanoma. Chemotherapy 53: 422-428, 2007. (Pubitemid 350085257)
21. Eklund JW, Trifilio S and Mulcahy MF: Chemotherapy dosing in the setting of liver dysfunction. Oncology (Williston Park) 19: 1057-1063, 2005. (Pubitemid 41725374)
22. McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, Frenette G, Puzanov I, Cranmer L, Lewis K, Kirkwood J, White JM, Xia C, Patel K and Hersh E: Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 26: 2178-2185, 2008.
23. Cranmer LD and Hersh E: The role of the CTLA4 blockade in the treatment of malignant melanoma. Cancer Invest 25: 613-631, 2007. (Pubitemid 350135746)
24. Richtig E, Ludwig R, Kerl H and Smolle J: Organ- and treatment-specific local response rates to systemic and local treatment modalities in stage IV melanoma. Br J Dermatol 153: 925-931, 2005. (Pubitemid 41540756)
25. McLoughlin JM, Zager JS, Sondak VK and Berk LB: Treatment options for limited or symptomatic metastatic melanoma. Cancer Control 15: 239-247, 2008.